intravenously (IV) with a proprietary rAAV capsid designated as SPK-9001 encoding a high activity FIX (Padua mutant) at a dose of 5e11 viral genome (vg)/kg and have shown persistence of transgene expression above the FIX therapeutic threshold up to 12-31 weeks (31.8% of normal FIX level) in the absence of any immunosuppressive regimen except for 2 out of 9 patients who showed asymptomatic liver enzyme elevation and developed immune response to AAV capsid (Table 1) . 7 In the uniQure trial, two cohorts of 5 patients were injected with a rAAV5 encoding for a codon-optimized FIX at doses of 5e12vg/kg and 2e13vg/kg. In comparison to the Spark Therapeutics trial, they have reported persistence of transgene expression above the FIX therapeutic threshold up to 6 months but at lower levels (5.1 to 13% of normal FIX level depending on the dose) despite much higher vector doses and in the absence of any immunosuppressive regimen except for 3 out of 10 patients ( Table 1) . 8 The results of these two studies suggest that, at least in the context of hemophilia B optimization of the expression cassette, the dose and/or the choice of AAV serotype can influence the initiation of an expression limiting immune response.
Finally and contrary to the results obtained by Manno et al. and Nathwani et al. in hemophilia B patients, two
clinical trials have shown that rAAV gene transfer may not only be reactivating cytotoxic T cell responses but is also able to initiate a regulatory T cell response. This was first described by Mueller et al. 9 in a phase 2b trial for alpha-1 antitrypsin deficiency (AATD) and later confirmed in a clinical trial with lipoprotein lipase-(LPL) 10 CTLA-4, HLA-DR or CD39 and downregulation of CD127 IL-7 receptor on mouse and/or human Tregs. [13] [14] [15] [16] [17] In addition to extracellular markers, intracellular markers such as the FoxP3 (forkhead box P3) transcription factor has been described as the most specific Treg marker in the thymus and in periphery. Foxp3 has shown its importance in the thymic development and suppressive activity of regulatory T cells. Indeed, the last point was supported by data suggesting that its expression in naïve T cells confers regulatory phenotype and function to those cells. [18] [19] [20] Another marker that has been recently identified is Helios, a member of the Ikaros transcription factor family that is expressed in natural and activated
Tregs and is also involved in Treg suppressive activities. 21, 22 During the past years, in vitro and in vivo studies have demonstrated that Tregs can mediate tolerance by interacting with cells in an APC-dependent or -independent manner, but also through the secretion of regulatory cytokines (Figure 1 ).
Tregs are able to interact with the CD8+ effector T cells by preventing proliferation and IFNγ secretion by CD8+ T cells without any interaction with APC. 23 They can also induce effector T cell death through the granzyme and perforindependent pathways. [24] [25] [26] In some cases, the immune regulation can be APC-dependent; Tregs have shown the ability to prevent dendritic cell (DC) maturation in vitro through down-regulation of CD80/CD86 costimulatory receptor expression by affecting the activation of effector T cells. 27-29 Moreover, regulatory T cells are also able to decrease the time of interactions between the CD4+ T cells and DC in vivo, as shown by 2-photon laser-scanning microscopy. 30, 31 Finally, the cytokine environment plays an important role in immune regulation. In fact, the regulatory cytokines: IL10, TGF-β or IL35 have shown the ability to convert naïve T cells to regulatory T cells by activating, for example, the Foxp3 pathway in these cells.
32-34
Despite the fact that regulation mechanisms are not completely understood, regulatory T cells play a major role in peripheral tolerance maintenance and autoimmune disease prevention. However, several studies have demonstrated that the induction or presence of preexisting Treg cells can also prevent effective virus clearance especially during chronic infections.
Regulation mechanisms in chronic infections
Regulatory T cell responses were initially described as regulators in a context of self-reactive antigen modulation in the thymus and autoimmune diseases. However, as mentioned above they have also been shown to be deleterious in animal This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. The AAV1 trials by Flotte et al. for the first time have shown that a tolerogenic response could be initiated after IM AAVbased gene transfer in humans. However, the mechanism remains to be established whether it is due to the dose, the transgene, and/or the administration route. There is some evidence to suggest that the mode of delivery and transgene could not be the only factors inducing this tolerance phenomenon because a previous clinical trial targeting LPL-deficient patients injected intramuscularly with a rAAV1 showed a loss of gene transfer efficacy after 18 to 31 months post dosing 48 probably related to an IFNγ immune response to AAV1 capsid ( Table 1) . 49 On the other hand, the same clinical trial performed more recently on patients transiently immunosuppressed described a continued transgene expression based on increased chylomicron turnover at 52 weeks and positive biopsies and showed evidence of infiltrated Treg in situ ( Table 1) .
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Consequences of immunosuppressive treatment in AAV-based gene transfer
Since a deleterious immune response to AAV capsid was described in patients in 2006, efforts were made to develop new strategies preventing this phenomenon. One of the strategies established was the use of immunosuppressant drugs. These protocols were first tested in animal models and inspired from immunosuppressive protocols developed to prevent graft rejection in transplantation and have shown mixed results. More recently glucocorticoid steroid immunosuppression has also been used in the context of human trials and has shown promising results after recombinant AAV gene transfer.
Immunosuppression protocols in animal models after AAV-based gene transfer.
Preclinical studies have shown the importance of immunosuppressant choice and combination. In one study, an ATG (anti-thymocyte globulin), cyclosporine, and mycophenolate mofetil (MMF) cocktail inducing T cell depletion, blocking transcription of cytokine genes and targeting activated T cells and primary antibody response respectively was used in Duchenne muscular dystrophy (DMD) dogs injected IM with an AAV6 vector encoding for the canine microdystrophin. 50 This cocktail allowed transgene expression persistence even after treatment interruption in areas without cellular infiltrates and these results were then confirmed in the same model after injection in several muscles; transgene expression was maintained until 1 year post dosing after immune suppressive treatment was stopped. On the contrary, the immune suppressive treatment might sometimes have a negative impact on gene transfer efficacy as described in a non-human primate (NHP) study. NHPs received an AAV2 vector encoding for FIX and were assigned to 3 groups receiving no immunosuppression, a combination of MMF, sirolimus (a potent inhibitor of antigen-induced proliferation of T cells and B cells) and daclizumab and a combination of MMF and sirolimus 1 week prior to dosing and maintained 10 weeks after liver-directed gene transfer. Surprisingly, the animals on 3-drug immunosuppressive (IS) regimen developed high titer inhibitory antibodies to FIX whereas monkeys receiving the vector alone or the 2-drug IS regimen did not and had sustained FIX expression. The 3-drug regimen also had a negative impact on antibodies to AAV2
capsid by showing higher antibody titer than monkeys receiving no IS or the 2-drug IS regimen where the titers were the lowest. In this study, the 3-drug IS regimen did not only show a boosting effect on the B-cell response but also a deleterious effect on the cellular immune response through a dramatic drop of Treg percentage. It was not the case when they receive the same regimen without the daclizumab. This phenomenon was explained by the fact that this drug is an antagonist of the CD25 receptor highly expressed on Tregs.
52
These studies highlight the importance of optimizing the immune suppressive regimens before protocol translations to humans. Immunosuppressive treatments have shown the ability to prevent immune responses to AAV capsid in humans affected by muscular dystrophies or metabolic disorders.
Use of immune suppressive drugs and/or regimen in AAV-based gene transfer clinical studies
The first evidence of the efficiency of immune suppressive drugs on immune response to AAV capsid in patients was described in 2011. Hemophilia B patients were injected with an AAV8 vector encoding for codon-optimized FIX transgene at different doses. On the contrary of preclinical studies described above or clinical trials cited below, the administration of immunosuppressive drug was not initially planned and occurred because patients receiving the highest dose (2e12 vg/kg) have shown an elevation of liver transaminases after 7 to 10 weeks post vector administration as already described. This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
specific T cell response demonstrating the effect of prednisolone on cellular immune response to AAV capsid occurring after gene transfer. 6 The last update was published in 2014, and the patients are still expressing the FIX 3 years after gene transfer. 53 Given that this was not a controlled clinical trial with two arms to explore the effectiveness of the prednisolone on curbing the immune clearance of AAV transduced hepatocytes it is yet to be determined if this intervention can be applied broadly.
The efficacy of this immunosuppressive regimen was also described in clinical trials targeting neuromuscular disorders however in this context they were designed to prevent or suppress immune responses to the transgene protein product and not necessarily to the AAV capsid. Patients suffering of muscular dystrophies are generally treated with glucocorticoids known to inhibit inflammation-associated molecules such as cytokines and chemokines, and prednisolone treatment in these patients has shown improvement of motor function and increased ambulation up to 1-3 years. However, the mechanism remains unknown. 54 The prednisolone was also used in two different clinical trials in LGMD (limb-girdle muscular dystrophy) and DMD patients to prevent cellular immune responses. The LGMD patients were off glucocorticoid treatment during the trial and 3 months before gene therapy. They received a boost of methylprednisolone 4 hours prior to dosing (2mg/kg IV) to prevent inflammation due to the needle. In patients injected with 3.25e11 vg of an AAV1 vector, no IFNγ response to AAV capsid was detected, despite CD4+ and CD8+ cell detection in situ and transgene expression having been observed for 3 months. 55 Regarding the immune response to the transgene, a clinical trial was performed on DMD patients using IM injection of an AAV1 vector encoding for the minidystrophin while patients underwent a standard glucocorticoid therapy and received methylprednisolone prior to dosing, as described previously. Surprisingly, 2 out of 6 patients showed an IFNγ cellular immune response to the dystrophin protein. These cells were already detected before injection, suggesting that these patients had a pre-existing immunity to the dystrophin probably due to the expression of this protein in revertant muscle fibers. 56 Thus, this immunosuppressive treatment does not seem to prevent the reactivation of specific-T cells to the transgene. The authors did not describe the cellular immune response to the capsid in this study.
More recently and in a different patient population, a transient prednisolone treatment resolved the episode of transaminase elevation in addition to a high IFNγ response to AAV9 capsid in spinal muscular atrophy (SMA) patients, which appeared 2 to 3 weeks after IV administration 57 ( Table 1) as already described in hemophilia B patients. All these trials described a persistence of transgene expression with a transaminase elevation episode resolved and a loss of IFNγ-secreted T cells detection after transient immunosuppressive treatment. However, the mechanism(s) responsible for induction of tolerance to AAV capsid, and in some cases to the transgene remain to be explored. Only one study in LPL deficient-patients has shown the evidence of Treg induction after AAV gene transfer associated to immune suppressive regimen.
As described earlier, the first clinical trial performed on LPL deficient-patients receiving an AAV1 vector encoding the LPL protein has shown an elevation of creatine kinase correlated to a dose-dependent activation of a capsid-specific T cell response limiting the duration of transgene expression. 49 The regulatory markers ( 9 and unpublished data), the infiltrated CD8+ T cells do not seem to present characteristics of cytotoxicity due to absence of expression of Granzyme B and Fas ligand. A further study regrouping analysis of exhausted T cell markers would be interesting to characterize the mechanism of tolerance involved.
Conclusion and future prospects
In the past decade, immunological research on AAV vectors has evolved considerably. Before translation to humans, rAAVs were considered as non-immunogenic vectors due to their low ability to transduce APC. 1 Now, we know that they single-stranded vectors and rAAV serotype 1, 2 and 6 are described to transduce murine 59 and human monocyte-or CD34 + -derived DC 60, 61 whereas serotype 8 presents a lower tropism to DC at least in vitro. 65 This difference of tropism for DC between the different serotypes and the genome conformation (ss versus sc vector) could explain why some serotypes are more immunogenic or on the opposite more tolerogenic than others. Further investigation of DC phenotype or functional maturation after rAAV transduction would be helpful to understand mechanisms involved in immune response initiation or reactivation and to modulate immune responses as described by Pandya et al. in an anti-tumor vaccine context. 66, 67 Despite that immune activating properties of rAAV are much reduced relative to other viral vectors like adenoviral or non-viral vectors.
A number of strategies have emerged to prevent adaptive immune responses to antigens such as the capsid and the transgene product by transient immune modulation. The duration of these treatments were based on studies suggesting that rAAV capsid do not persist more than 6 to 8 weeks, depending on serotypes, after gene transfer. 68 However, past and recent studies have demonstrated that AAV capsid can be detected up to 6 years after gene transfer depending on the administration route. Studies on NHP have shown that 6 years after subretinal injections, rAAV2 and rAAV5 capsids were still detected in the retina. 69 More recently, Mueller et al. described the AAV1 capsid persistence in the muscle 1 year after IM injection. 9 These observations support that AAV vector gene transfer could mimic a chronic infection due to the epitope persistence in situ. This hypothesis is also supported by the detection of Tregs and exhausted T cells in situ as described in two different clinical trials. 9, 10 However, the mechanisms initiating the regulation are still unknown; to date, we cannot conclude whether the persistent antigen exposure leads to T cell exhaustion and/or Treg initiation or whether This article has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. as been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from Gernoux_Table1 Human Gene Therapy
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